J&J, Vivus patent suit ends

Share this content:

Johnson & Johnson's Janssen subsidiary has walked away from a lawsuit against drugmaker Vivus over patents using the anti-seizure medication topiramate for a variety of medical conditions.

Vivus, in turn, has agreed to pay a one-time fee and royalty on its FDA-approved weight-loss drug Qsymia, which combines phentermine and topiramate.

Share this content:
Scroll down to see the next article